propranolol / Generic mfg. - LARVOL DELTA

Functional assessment of cardiac beat dynamics under dynamic flow: insights from the Mera microphysiological system. (PubMed, Biomed Microdevices) - "Pharmacological testing with verapamil, isoproterenol, calcium chloride, and propranolol demonstrated real-time, reversible modulation of beat rate under flow, including recovery following drug-induced suppression. Collectively, these results demonstrate that Mera provides a reproducible, human-relevant platform for modelling cardiomyocyte beat-rate responses to pharmacological modulation under dynamic flow. By enabling dynamic drug exposure and automated analysis, Mera represents a promising approach methodology (NAM) for cardiac drug response testing; incorporation of contractility and electrophysiological readouts will be an important next step toward supporting its use in predictive cardiac safety assessment."

Journal • Cardiovascular

Obstructive Shock From Suicide Left Ventricle After Transcatheter Aortic Valve Replacement. (PubMed, JACC Case Rep) - "Dynamic left ventricular outflow tract obstruction should be suspected in early post-TAVR shock."

Journal • Cardiovascular

Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer (clinicaltrials.gov) - P2 | N=46 | Not yet recruiting | Sponsor: University of Southern California

New P2 trial • Hepatocellular Cancer • Liver Cancer • Melanoma • Oncology • Solid Tumor

An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma (ASH 2025) - P2 | "Mediantimes to neutrophil and platelet engraftment were 11 days (range 11-17 days) and 15 days (range 11-27days), respectively.ConclusionsBurixafor, in combination with propranolol and G-CSF, demonstrated an excellent safety profile andeffectively mobilized sufficient HPCs for AHCT, including patients previously treated with lenalidomideand daratumumab. Notably, burixafor enabled same-day administration with leukapheresis, offering akey advantage over other CXCR4 inhibitors, such as plerixafor and motixafortide through its rapidmobilization kinetics. Its favorable safety profile, characterized by minimal adverse events, supporting itspotential clinical utility."

Clinical • IO biomarker • P2 data • Cardiovascular • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hypotension • Multiple Myeloma • Musculoskeletal Diseases • Musculoskeletal Pain • CD34 • CXCR4

Thoracoscopic diaphragmatic plication technique in a patient with refractory hepatic hydrothorax (PubMed, Rev Med Inst Mex Seguro Soc) - "Diuretic therapy with propranolol, furosemide, and spironolactone was administered, along with sodium restriction (80-90 mEq/day) and fluid restriction (< 2 L/day), without improvement and with symptom progression. Chemical pleurodesis induces pleural adhesion and obliteration of the space. The combination of both techniques increases therapeutic effectiveness."

Journal • Cardiovascular • Fibrosis • Hepatology • Hypertension • Immunology • Pain • Portal Hypertension • Primary Biliary Cholangitis • Pulmonary Disease • Respiratory Diseases

Improved outcomes for patients with autonomic movement disorders originally evaluated for psychogenic non-epileptiform spells. (PubMed, Front Neurol) - "14 of 17 patients were started on at least one medication for symptom management, including fludrocortisone, pyridostigmine, midodrine, and propranolol, with 8 of 17 on combination therapy. Patients presenting with abnormal seizure-like movements confirmed as non-epileptic after further evaluation should be assessed for autonomic dysfunction. Treatment targeting orthostatic hypotension may help alleviate these abnormal movements."

Journal • CNS Disorders • Epilepsy • Hypotension • Movement Disorders

Exploring Thyrotoxic Hypercalcaemia Through Two Cases: A Myriad of Uncertainties. (PubMed, Case Rep Endocrinol) - "Both patients improved clinically and biochemically with adequate intravenous hydration, frusemide, carbimazole, propranolol, and bisphosphonates. Prompt recognition and management is essential to prevent bone loss, correct metabolic abnormalities, and avoid complications. Clinicians should also consider the possibility of hypercalcaemia associated with thyroid dysfunction in patients presenting with nonspecific symptoms such as fatigue, constipation, proximal weakness, polyuria, or mood changes."

Journal • Constipation • Endocrine Disorders • Fatigue • Gastroenterology • Gastrointestinal Disorder • Mood Disorders • Ophthalmology • Osteoporosis • Pain • Psychiatry • Pulmonary Disease • Renal Disease • Rheumatology

Semi-automated erythema quantification in infantile haemangioma receiving propranolol: a pilot feasibility study. (PubMed, Pediatr Surg Int) - "Semi-automated erythema quantification from clinical photographs of IH is feasible with high intra-rater reliability. These pilot findings should be interpreted as hypothesis-generating; the study is underpowered for definitive correlation testing, and prospective replication in an adequately powered cohort is required. In this pilot cohort, colour-based EI change alone was insufficient to track the clinician's composite response assessment under real-world uncalibrated photography conditions, consistent with the partial-biomarker nature of colour-only analysis. Prospective studies with standardised photography incorporating colorimetric calibration and composite colour-plus-area scoring are warranted."

Journal • Retrospective data • Dermatology • Oncology • Pediatrics

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma (clinicaltrials.gov) - P2/3 | N=32 | Recruiting | Sponsor: West China Hospital | N=24 ➔ 32 | Trial completion date: Aug 2026 ➔ Mar 2027 | Trial primary completion date: Jun 2026 ➔ Sep 2026

Enrollment change • Trial completion date • Trial primary completion date

Beta-Blockers for the Treatment of Arrhythmias: Which Drug for Which Arrhythmia? A State-of-the-Art Narrative Review. (PubMed, Am J Cardiovasc Drugs) - "In adrenergically mediated inherited syndromes, namely catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, nonselective agents and especially nadolol are clearly superior to beta1-selective agents, and the same principle appears to extend to ventricular electrical storm, in which propranolol has outperformed metoprolol in a randomized comparison. In acute care, pharmacokinetics dominate, and the ultra-short-acting agents esmolol and landiolol permit a degree of titration that longer-acting drugs cannot match. In patients with heart failure and reduced ejection fraction, carvedilol, metoprolol succinate, and bisoprolol should be preferred irrespective of arrhythmia subtype because of their established mortality benefit. Conversely, beta1-selective agents, including the highly selective agent nebivolol, improve tolerability in bronchospastic disease, although this reflects respiratory tolerability rather than any demonstrated antiarrhythmic..."

Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Ventricular Tachycardia

A Creepy Case of Recurrent Stridor: Circumferential Subglottic Hemangioma Diagnosed by Empiric Propranolol. (PubMed, Ear Nose Throat J) - "The infant's stridor improved dramatically within five days and resolved completely; she was discharged after a one-month neonatal intensive care unit stay and remained asymptomatic at seven-month follow-up. This case illustrates the diagnostic ambiguity that can attend circumferential subglottic narrowing in the neonate and demonstrates that empiric propranolol can serve as both a diagnostic and therapeutic trial when imaging is unrevealing."

Journal • Critical care • Hematological Disorders • Pediatrics

Discovering repurposable drugs for Alzheimer's disease and related dementias: target trial emulation using decentralised real-world data. (PubMed, EBioMedicine) - "20 widely used medications may be associated with reduced progression from MCI to ADRD and represent promising candidates for clinical evaluation as repurposed therapies for dementia."

Journal • Real-world evidence • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Pain

Efficacy and Tolerability of Atenolol vs. Propranolol in Treating Infantile Hemangiomas (EADV 2026) - No abstract available

Clinical • Vasculitis

Severe PHACE Syndrome Associated With Extensive Segmental Infantile Hemangioma Successfully Treated With Early Propranolol Therapy (EADV 2026) - No abstract available

Vasculitis

Evaluating Neurodevelopmental Sequelae of Propranolol Use in Infantile Hemangioma: A Large-Scale Population-Based Study (EADV 2026) - No abstract available

Clinical • Neurodevelopmental • Dermatology • Pediatrics

Sensitive electrochemical sensor for selective detection of chiral amino acids based on covalent organic framework-cyclodextrin-gold nanocomposite. (PubMed, Anal Chim Acta) - "The enantioselectivity of the sensor was evaluated by monitoring methylene blue redox signals, enabling chiral discrimination of phenylalanine, tryptophan, tyrosine, histidine, propranolol, and naproxen. COF-V substrate enhanced electrode surface area and stability. Synergy of AuNPs-cyclodextrin and chitosan for improving chiral recognition."

Journal

Vocal Tremor as the Initial Manifestation of Palatal Tremor with Response to Propranolol : A Case Report (MDS Congress 2026) - No abstract available

Case report • Clinical • CNS Disorders • Movement Disorders

Ulixacaltamide Demonstrates Superiority Over Placebo as Monotherapy and as Add-on to Propranolol in Essential Tremor: Phase 3 ESSENTIAL3 Study 1 (MDS Congress 2026) - No abstract available

Clinical • Head-to-Head • Monotherapy • P3 data • CNS Disorders • Essential Tremor • Movement Disorders

The application of nanoparticles green-formulated by Lycium barbarum leaf aqueous extract in the treatment of myocardial infarction. (PubMed, Discov Nano) - "The present study offers a contemporary corrective approach for the myocardial infarction therapeutic management."

Journal • Cardiovascular • Myocardial Infarction

Infantile hemangiomas: diagnosis and modern therapeutic approaches (PubMed, Ophthalmologie) - "A thorough understanding of the different types of hemangiomas, their clinical presentations, and the indications for further diagnostic evaluation is essential for optimal patient care. Therapeutically, propranolol has become established as an effective and safe first-line treatment for complicated infantile hemangiomas."

Journal • Oncology

Clinical Characteristics, Management, and Complications of Infantile Hemangiomas Involving the Ear and Periauricular Region. (PubMed, Pediatr Dermatol) - "Given their location and potential for anatomic deformity and functional impairment, ear and periauricular IH may require intervention. A majority of patients in this cohort required treatment, most commonly for risk of anatomic deformity. The study is limited by the retrospective design and inclusion of patients seen before beta-blockers were available for IH management."

Journal • Otorhinolaryngology • Pediatrics

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparison table: Some drugs for migraine prevention. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Application of Propranolol Combined with Neoadjuvant Endocrine Therapy in Prostate Cancer: An Open-label Safety Exploratory Study (ChiCTR) - P=N/A | N=12 | Not yet recruiting | Sponsor: The Third Affiliated Hospital Sun Yat-sen University; The Third Affiliated Hospital Sun Yat-sen University

New trial • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Sympathetic Hyper-Activation Promotes Lung Cancer Bone Metastasis by Upregulation of Immune Checkpoint Molecules and Osteoclastogenesis (IASLC-WCLC 2026) - "Pharmacologic activation of beta-adrenergic signaling induced similar effects, and treatment of beta-antagonist propranolol reversed PD-L1 expression and osteoblast cell differentiation, additionally enhance the effect of anti-PD-1 treatment. Conclusions : These finding identify the status of NE and activation of the sympathetic nervous system as a novel neural regulator of bone metastasis. Thus, targeting ADRB2 can be a potent approach for combating bone-metastases of lung cancer."

IO biomarker • Lung Cancer • Oncology • Osteosarcoma • Solid Tumor • ADRB2 • PD-L1